Cantargia AB (publ)
CANTA
Rank in Stocks
#23221
Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in... Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to target Interleukin-1 Receptor Accessory Protein (IL1RAP). This innovative treatment aims to identify and stimulate the immune system to destroy cancer cells, while also mitigating tumor-related inflammation fueled by the Interleukin-1 system, and is currently in Phase IIa clinical trials. The company is also advancing CAN10, another IL1RAP-specific antibody, through preclinical development for autoimmune and inflammatory conditions like systemic sclerosis and myocarditis. Additionally, Cantargia is exploring other CANxx antibodies that also interact with IL1RAP. The manufacturing and production of CAN04 are facilitated through partnerships with Patheon Biologics BV and BioWa Inc., and its clinical study is supported by Specialized Medical Services-oncology BV.
Share Price
$0.15783444
Last synced: 2026-11-09
Market Cap
$44.50M
Change (1 day)
-2.73%
Change (1 year)
-58.76%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cantargia AB (publ) (CANTA)
Category
Healthcare
Operating Margin for Cantargia AB (publ) (CANTA)
Operating Margin as of November 2026 TTM: 51.45%
According to Cantargia AB (publ)'s latest financial reports, its current operating margin (TTM) is 51.45%. At the end of 2025 the company had an operating margin of 48.75%.
Operating Margin history for Cantargia AB (publ) from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 51.45% | 5.54% |
| 2025 | 48.75% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -99.25% |
US
|
|
| -149.01% | -102.90% |
US
|
|
| 25.57% | -99.50% |
AU
|
|
| 31.23% | -99.39% |
BE
|
|
| 29.35% | -99.43% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Cantargia AB (publ)'s operating margin
What is Cantargia AB (publ)'s operating margin?
Cantargia AB (publ)'s operating margin is 51.45%, as of Nov 2026.
What was Cantargia AB (publ)'s operating margin in 2025?
In 2025, Cantargia AB (publ)'s operating margin was 48.75%, compared with 0.00% in 2024.
How has Cantargia AB (publ)'s operating margin changed since 2020?
From 2020 to 2025, Cantargia AB (publ)'s operating margin was highest in 2025 (48.75%) and lowest in 2024 (0.00%).
How does Cantargia AB (publ)'s operating margin compare with similar companies?
Cantargia AB (publ)'s operating margin (51.45%) is higher than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.